The most recent trading session ended with Agilent Technologies (A) standing at $132.97, reflecting a -0.06% shift from the previouse trading day's closing. The stock fell short of the S&P 500, which registered a gain of 1.07% for the day. Elsewhere, the Dow gained 0.35%, while the tech-heavy Nasdaq added 1.74%.The the stock of scientific instrument maker has risen by 1.56% in the past month, lagging the Computer and Technology sector's gain of 4.83% and the S&P 500's gain of 2.93%.Market participants will ...

Investors with an interest in Electronics - Testing Equipment stocks have likely encountered both Fortive (FTV) and Agilent Technologies (A) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with str ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced an agreement with Incyte that will bring together Agilent’s expertise and proven track record in the development of companion diagnostics (CDx) to support the development and commercialization of Incyte’s hematology and oncology portfolio. The value of the companion diagnostics market is predicted to expand to nearly US $14B by 2030,1 driven in part by the power of these tests to inform treatment decisions for a gro ...

The latest trading session saw Agilent Technologies (A) ending at $130.99, denoting a +0.85% adjustment from its last day's close. The stock outpaced the S&P 500's daily loss of 0.07%. On the other hand, the Dow registered a gain of 0.16%, and the technology-centric Nasdaq decreased by 0.36%.Heading into today, shares of the scientific instrument maker had lost 7.08% over the past month, lagging the Computer and Technology sector's gain of 5.93% and the S&P 500's gain of 3.05% in that time.Analysts and inve ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the first quarter of fiscal year 2024 after the stock market closes on Tuesday, Feb. 27. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST. To join the listen-only conference call webcast, click the link on the Events section of Agilent’s investor relations website. A recording of the call will also be available on the website for 90 days. About Agilent Te ...

Over the past 80 years, the United States faced a persistent issue of in-state manufacturing decline, marked by a shift towards research and development rather than domestic production. The trend led to a significant loss of manufacturing jobs, peaking in the 2000s with a 33% decrease. However, technology is now reshaping U.S. manufacturing, offering a modern and advanced system. Investing in this upward trend, with an expected 5.2% rise in wages and benefits, can usher in a prosperous new era for American ...

To boost capabilities in protein analysis, Agilent Technologies (A) announced the launch of the Agilent ProteoAnalyzer system.The Agilent ProteoAnalyzer system is a new automated parallel capillary electrophoresis system for protein analysis that brings more efficiency, versatility and reliability in protein QC workflows by automating the separation, data processing and simplifying sample preparation steps.This way, it analyzes complex protein mixtures seamlessly.It is designed to analyze different sizes an ...

Investors looking for stocks in the Electronics - Testing Equipment sector might want to consider either Fortive (FTV) or Agilent Technologies (A) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks wi ...

ValeryEgorov Step one: Wide-moat stocks with 5-star and 4-star ratings Historical evidence says that while quality alone is a poor indicator of outperformance, when combined with a decent valuation filter, Morningstar’s moat rating proves to be more than useful. Based on the available data, stocks with a wide-moat rating that also fit into the 4- or 5-star category deserve to be the subject of further analysis. See the detailed explanation and the underlying evidence of our first step in this article. W ...

Core Viewpoint - Agilent Technologies is well-positioned for long-term growth despite recent market challenges, supported by a diversified business model and multiple growth drivers [2][4][30]. Financial Performance - In 2023, Agilent reported $6.8 billion in revenue, achieving a four-year compound annual growth rate (CAGR) of 7% [3]. - The company has maintained a profitability margin of 27.4%, with an average margin growth of 100 basis points per year over the last four years [3][5]. - Earnings per share (EPS) have grown at an average rate of 15% annually over the past four years [3]. Business Diversification - Agilent's business is diversified, with 40% in instrumentation and 60% in services, consumables, diagnostic tests, and software [3][16]. - The company operates across six end markets, with pharmaceuticals being the largest, accounting for approximately 36% of total business [4][11]. Growth Strategy - Agilent aims for core revenue growth of 4% to 7% in the long term, with expectations for operating margin expansion of 50 to 100 basis points per year [4][5]. - The company has invested over $4.6 billion since 2015 to drive future growth, with $3 billion allocated to mergers and acquisitions [7][8]. Market Outlook - The total addressable market (TAM) for Agilent is estimated at $65 billion, with long-term growth prospects of 4% to 6% [9][10]. - Key growth drivers include advancements in human health, environmental sustainability, and food safety [10][23]. Segment Performance - The biopharma segment has shown resilience, with Agilent's biopharma business nearly doubling and now representing over 40% of total pharma business [17][19]. - The applied markets segment grew by 3% in 2023, driven by demand for PFAS testing and advanced materials [13][24]. Regional Growth - Agilent has experienced growth of 6% to 8% across five major geographies over the last four years, indicating strong local market strategies [15]. - The company anticipates a recovery in the Chinese market, projecting a return to growth by 2025 [60][65]. Innovation and Technology - Agilent is focusing on integrating AI into its operations and customer offerings to enhance efficiency and product development [25]. - The company is also investing in sustainability solutions, including refurbished products and environmentally friendly practices [26][27]. Future Guidance - For fiscal 2024, Agilent expects net revenue between $6.71 billion and $6.81 billion, with core revenue growth projected at 0.5% to 1% [29][39]. - The company remains committed to delivering leveraged earnings growth, aiming to grow earnings faster than revenue [29].